Expression of ANXA2 in the Extracellular Space in the Microenvironment of Periumoral Edema Promotes Glioma Invasion

Glioma Clinical Trial

Official title:

Study on the Mechanism of the Expression of ANXA2 in the Extracellular Space in the Microenvironment of Periumoral Edema to Promote Glioma Invasion

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04953468
• Other study ID #: M2021020
• Status: Recruiting
• Start date: February 19, 2021
• Est. completion date: August 1, 2023

Study information

• Verified date: July 2021
• Source: Peking University Third Hospital
• Contact: Yang Jun
• Phone: 13901291211
• Email: 13901291211[@]163.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The prognostic value of ANXA2 expression in tumor tissue and PTBE was analyzed, so as to seek new therapies to inhibit glioma invasion and improve the prognosis of glioma patients

Description:

The main reason for the poor prognosis of glioma is the invasion of tumor cells along the extracellular space (ECS) in the periatumoral edema zone (PTBE).Previous studies have shown that ANXA2 is highly expressed in glioma and promotes tumor growth and invasion, while its expression in the PTBE microenvironment of glioma and its mechanism of action on tumor invasion have not been reported.Previous study found that ANXA2 was overexpressed in gliomas and was associated with poor prognosis, and the low expression of ANXA2 significantly inhibited tumor invasion in vitro.Relevant studies have also confirmed that as an exocrine protein, it mainly plays a role in ECS, and it has previously been carried out on the tissue structure of ECS in tumor microenvironment.Therefore, investigators planned to study the mechanism of ANXA2 expression in PTBE microenvironment ECS on tumor invasion.This project aims to take glioma related issues as the research object and analyze tumor tissue and tumor tissue

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 130
• Est. completion date: August 1, 2023
• Est. primary completion date: August 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Patients who have undergone microneurosurgical resection of the tumor in our hospital and are pathologically confirmed to be supratentorial glioma;

• Preserving the remaining tissue samples of paired gliomas and PTBE for pathological examination;

• The patients agreed to be enrolled and signed the informed consent;

• The clinical data of the patients are complete and not lost;

• No serious complications occurred after surgery.

Exclusion Criteria:

• All glioma patients who did not meet the inclusion criteria

Related Conditions & MeSH terms

• Glioma

Intervention

Diagnostic Test:
• expression level of ANXA2 protein
The expression level of ANXA2 protein in glioma and PTBE was detected by immunohistochemistry

Locations

Country	Name	City	State
China	Peking University Third Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Peking University Third Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall survival	Follow-up information was collected by telephone follow-up and regular review when patients returned to the hospital. Telephone follow-up was conducted every 3 months, and the main follow-up content was survival time, and the end point of follow-up was to the patient's death	From the date of surgery to the date of death from any cause, assessed up to 18 weeks.